Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment.

iScience·2026
Same author

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.

Cancer research·2025
Same author

Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.

Cancer research·2025
Same author

Sparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer<sup>†</sup>.

The Journal of pathology·2025
Same author

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer.

Cell reports. Medicine·2025
Same author

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers.

Science translational medicine·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 18, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.1K

Mutant ARID1A: igniting cancer immunotherapy.

Bujamin H Vokshi1, Eneda Toska2

  • 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Trends in Immunology
|July 27, 2024
PubMed
Summary

Loss of ARID1A boosts anti-cancer immunity by activating the cGAS-STING pathway and type I IFN response. This promotes T cell activity, suggesting SWI/SNF inhibitors can improve cancer immunotherapy effectiveness.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

Related Experiment Videos

Last Updated: Jun 18, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.1K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The SWI/SNF chromatin remodeling complex plays a crucial role in cancer development.
  • ARID1A is a frequently mutated gene in various cancers, but its role in antitumor immunity is not fully understood.

Purpose of the Study:

  • To investigate the impact of ARID1A loss on the tumor microenvironment and immune response.
  • To explore the potential of targeting the cGAS-STING pathway in ARID1A-deficient tumors.

Main Methods:

  • Utilized genetically engineered mouse models with ARID1A loss.
  • Analyzed immune cell infiltration and activation using flow cytometry and immunohistochemistry.
  • Assessed type I interferon (IFN) signaling and downstream pathways.

Main Results:

  • ARID1A loss triggers a robust type I IFN response via the cGAS-STING pathway.
  • This response enhances T cell infiltration and cytotoxic activity within the tumor.
  • Tumors with ARID1A loss exhibit increased sensitivity to immunotherapy.

Conclusions:

  • Loss of ARID1A functions as a neoantigen, activating intrinsic antitumor immunity.
  • Targeting SWI/SNF pathways, particularly ARID1A loss, represents a promising strategy to enhance immunotherapy efficacy.
  • These findings pave the way for novel therapeutic approaches in cancer treatment.